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Skeletal muscle mitochondrial dysfunction and insulin
resistance occur in chronic kidney disease. Ghrelin is a gastric
hormone previously shown to enhance muscle mitochondrial
enzyme activities and AKT-mediated insulin signaling
independent of food intake in healthy rats. Here we
determined the impact of ghrelin treatment on anorexia,
skeletal muscle mitochondrial oxidative capacity, AKT
phosphorylation as a measure of insulin signaling, and lean
body mass in a rat model of chronic kidney disease. Ghrelin
infusion promoted higher food intake and lean body mass.
Further, although muscle mitochondrial enzyme activities
were low in the rats with CKD (chronic kidney disease), they
normalized with ghrelin treatment, a change that was
consistent with the increase in the transcript levels of
regulators of mitochondrial biogenesis and lipid metabolism.
This was associated with a lower muscle triglyceride content
and higher AKT phosphorylation. Pair-feeding showed that
mitochondrial effects of ghrelin are independent of changes
in food intake, whereas combined ghrelin treatment and
higher food intake were needed to enhance AKT
phosphorylation. Thus, ghrelin-induced muscle
mitochondrial changes and lower tissue triglycerides could
favor insulin action and muscle anabolism in the presence of
improvement in food intake. Our study shows that combined
effects of ghrelin on appetite and muscle mitochondria
improve muscle metabolic and nutritional alterations in
chronic kidney disease. This could have potential beneficial
impact on patient morbidity and survival.
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Skeletal muscle mitochondrial dysfunction1,2 and insulin
resistance3,4 have been reported in advanced chronic kidney
disease (CKD). These changes are proposed to be causally
associated in several disease models5,6 and they may contribute
to reduced CKD patient survival because of metabolic and
cardiovascular morbidity and mortality.3,7 Low mitochondrial
oxidative capacity and insulin resistance could also contribute
to CKD-associated muscle wasting and cachexia, with added
negative prognostic impact.3,4,7 Ghrelin is a gastric orexigenic
hormone,8,9 the administration of which was previously shown
to enhance muscle mitochondrial enzyme activities and AKT-
mediated insulin signaling independently of food intake in
healthy rats.10,11 Consistent with these findings, positive associa-
tions are reported between total circulating ghrelin and insulin
sensitivity in humans.12,13 A direct association was also recently
shown between insulin-mediated glucose disposal and plasma
ghrelin concentration in nondiabetic uremic patients undergoing
maintenance hemodialysis.14 Ghrelin has been reported to reduce
anorexia and attenuate body weight loss through selective
preservation of lean mass in wasting-associated chronic disease
models, including cancer and CKD.15,16 Mechanisms of ghrelin
anticatabolic effects are, however, only partly understood, and
potential changes in skeletal muscle mitochondrial oxidative
capacity, lipid content, and AKT phosphorylation after ghrelin
treatment in CKD are not known.
In this study, we tested the hypotheses that ghrelin adminis-
tration in a subtotal nephrectomy rat model prevents a CKD-
associated reduction of mitochondrial oxidative capacity, as
reflected by representative mitochondrial enzyme activities, and
that these changes are associated with a higher transcriptional
expression of mitochondrial biogenesis stimulators (including
peroxisome proliferator activated receptor-g-coactivator-1a
(PGC-1a) and -b, (PGC-1b)).17 We further hypothesized that
mitochondrial effects lead to a lower tissue triglyceride content,
higher activation of insulin signaling at the AKT phosphorylation
level, and improvement in plasmametabolic profile. To dissect the
potential independent role of attenuated anorexia in metabolic
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changes, the effects of ghrelin treatment were studied in both
ad libitum-fed animals and in rats pair-fed to the spontaneous
food intake level of the untreated nephrectomized group.
RESULTS
Food intake, body weight, and plasma metabolic profile
Nephrectomy (Neph) caused kidney failure as shown by
comparable increments in plasma creatinine in both Neph
groups (Sham-Saline: 0.24±0.02mg/dl, N¼ 5 (Po0.001 vs
both Neph groups); Neph-Saline: 1.18±0.16mg/dl, N¼ 8;
and Neph-Ghrelin: 1.00±0.04mg/dl; N¼ 11) and in blood
urea nitrogen level (Sham-Saline: 13.4±1.03mg/dl, N¼ 5
(Po0.001 vs both Neph groups); Neph-Saline:
76.8±11.8mg/dl, N¼ 8; and Neph-Ghrelin: 64.4±3.9mg/
dl, N¼ 11).16 Neph-Saline had a lower cumulative food
intake that was increased (although not normalized) by
ghrelin treatment (Sham-Saline: 224±8.5 g, N¼ 5 (Po0.05
vs other groups); Neph-Saline: 139±6.3 g, N¼ 8; and Neph-
Ghrelin: 166±4.3 g, N¼ 11 (Po0.05 vs Neph-Saline)).
Neph-Saline showed a lower gain of total and lean body
mass during the study period, with a net loss of fat mass
(Table 1). Ghrelin treatment reduced the loss of total and lean
body mass, but not that of fat mass (Table 1). Plasma glucose
was lower in ghrelin-treated than in both control and saline-
treated CKD animals (Po0.05), whereas no changes were
observed in plasma insulin and triglyceride concentrations
(Table 2). Total plasma adiponectin was high in nephrecto-
mized rats treated with saline compared with sham control
animals with no effect of ghrelin treatment (Table 2).
Skeletal muscle mitochondrial enzyme activities and
mitochondrial biogenesis transcript levels
Subtotal nephrectomy was associated with lower skeletal
muscle activities of both cytochrome c oxidase (Po0.05) and
citrate synthase (P¼ 0.052 vs Sham) (Figure 1), and this
alteration was associated with lower transcript levels of
master regulators of mitochondrial biogenesis and lipid
oxidation such as PGC-1a, PGC-1b, mitochondrial tran-
scription factor A (mTFA), and peroxisome proliferator
activated receptor-a (Figure 2). Ghrelin treatment was in
turn associated with higher activities of both enzymes
compared with the saline-treated group (Po0.05 vs Neph-
Saline, P¼NS vs Sham) (Figure 1). Transcript levels of
PGC-1a, PGC-1b, and peroxisome proliferator activated
receptor-a were also higher after ghrelin treatment than in
saline-treated CKD animals (Po0.05 vs Neph-Saline, P¼NS
vs Sham), whereas ghrelin-induced increment in the mito-
chondrial transcription factor A transcript level was smaller
and not statistically significant (Figure 2).
Skeletal muscle triglyceride content and AKT
phosphorylation
A nonsignificantly higher skeletal muscle triglyceride content
and lower AKT phosphorylation were observed in saline-
treated nephrectomized rats compared with control animals.
Ghrelin treatment was in turn associated with lower
triglyceride content and higher AKT phosphorylation
compared with saline-treated nephrectomized animals (both
Po0.05 for Neph-Ghrelin vs Neph-Saline; P¼NS for Neph-
Ghrelin vs Sham).
Relative impact of ghrelin and attenuated anorexia on
mitochondrial lipid metabolism and insulin signaling
We further investigated whether changes in mitochondrial
oxidative capacity and AKT phosphorylation were due to
ghrelin treatment per se or due to induction of enhanced food
intake. Toward this aim, an additional group of rats were
nephrectomized and treated with ghrelin infusion using
Table 1 | Percent cumulative changes in total body mass, lean
mass, and fat mass (from days 0 to 14 of ghrelin or saline
infusions) in the four experimental groups
Sham-
Saline
Neph-
Saline
Neph-
Ghr
Neph-
GhrPF
Body mass (%) 29.2±6.7a 2.4±1.9b 22.2±2.7a 3.7±0.4b
Body fat mass (%) 15.6±12.8a 40.2±4.3b 30.4±5.6b 28.7±1.4b
Body lean mass (%) 30.3±7.3a 2.2±1.9b 26.3±2.5a 4.1±0.5b
Ghr, ghrelin; Neph, nephrectomy; PF, pair-feeding.
a,bDifferent letters denote statistically significant differences (Po0.05).
Table 2 | Plasma insulin, glucose, triglyceride, and total
adiponectin concentrations in the four experimental groups
Sham-
Saline
Neph-
Saline
Neph-
Ghr
Neph-
GhrPF
Insulin (ng/ml) 3.2±1.1a 4.2±0.4a 4.2±1a 4.3±1.1a
Glucose (mg/dl) 99±7a 96±2a 87±4b 84±3b
Triglycerides (mg/dl) 144±11a 152±16a 139±21a 132±16a
Adiponectin (mg/ml) 3.4±0.2a 7.6±0.8b 6.9±0.6b 8.1±1.4b
Ghr, ghrelin; Neph, nephrectomy; PF, pair-feeding.
a,bDifferent letters denote statistically significant differences (Po0.05).
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Figure 1 |Mitochondrial enzyme activities. Skeletal muscle
activities of cytochrome c oxidase (COX) (a) and citrate synthase
(CS) (b) in the experimental groups; *Po0.05. Ghr, ghrelin;
Neph, nephrectomy; PF, pair-feeding; S, saline.
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procedures and doses identical to those used in Neph-Ghrelin
(Neph-GhrelinPF: Materials and Methods), except for pair-
feeding to the food intake level of the Neph-Saline group.
Neph-GhrelinPF had moderately but significantly lower
plasma glucose level (84±3mg/dl, Po0.05 vs Neph-Saline)
with insulin (4.3±1.1 ng/ml) and total adiponectin
(8.1±1.4mg/ml), comparable with other nephrectomized
groups. Ghrelin treatment enhanced and normalized the
activities of both mitochondrial enzymes in the absence of
enhanced food intake as well (Figure 1). This effect was
associated with higher and normalized transcript levels of
PGC-1a, PGC-1b, mTFA, and peroxisome proliferative
activator receptor-a (Figure 2), as well as with lower muscle
triglyceride content (Figure 3a). On the other hand, the
increase in AKT activation did not reach statistical signifi-
cance during ghrelin treatment in the absence of an elevation
of food intake (Figure 3b). Prevention of spontaneous
elevation of food intake was associated with a lack of
attenuation of lean body mass loss, and both fat and lean
mass changes were comparable in pair-fed and nephrecto-
mized, saline-treated animals (Table 1). Gastrocnemius
muscle weight at the time of killing was also similarly lower
in the saline-treated and pair-fed ghrelin-treated animals
compared with that in the sham control group (data not
shown).
DISCUSSION
The main findings of this study are that in this rat model (a)
CKD is associated with an early impairment of skeletal
muscle mitochondrial oxidative capacity with a low expres-
sion of mitochondrial biogenesis and lipid oxidative
metabolism regulators; (b) ghrelin treatment normalizes
altered mitochondrial oxidative capacity and transcriptional
expression of mitochondrial regulatory genes, associated
with lower muscle triglyceride content and lower plasma
glucose independently of changes in food intake; (c) in
ghrelin-treated animals, attenuation of anorexia is further
associated with stimulation of AKT phosphorylation and
preserved lean mass, which are in turn prevented in the
absence of food intake elevation.
Although ghrelin administration has been proposed as a
treatment for wasting in chronic diseases because of its effects
to enhance appetite and fat mass,8,9,18 ghrelin has also been
shown to modulate energy lipid metabolism in nonfat tissues,
including skeletal muscle.10,11 The effects of ghrelin to
enhance skeletal muscle mitochondrial oxidative capacity
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Figure 2 |Mitochondrial biogenesis and lipid metabolism regulators. Skeletal muscle transcript levels of peroxisome proliferator-
activated receptor-g coactivator 1-a (a; PGC1-a), peroxisome proliferator-activated receptor-g coactivator 1-b (b; PGC1-b), mitochondrial
transcription factor A (c; mTFA), peroxisome proliferator-activated receptor-a (d; PPAR-a) in the experimental groups; *Po0.05. Ghr, ghrelin;
Neph, nephrectomy; PF, pair-feeding; S, saline.
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Figure 3 |Muscle triglycerides and AKT phosphorylation.
Skeletal muscle triglycerides (a) and the ratio (P/T) of phosphorylated
(P) to total (T) AKT protein (b) in the experimental groups.
Representative bands from western blotting for P- and T-AKT are
shown under each bar. *Po0.05. Ghr, ghrelin; Neph, nephrectomy;
PF, pair-feeding; S, saline.
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are of significance in CKD, as muscle mitochondrial enzyme
activities and oxidative capacity were reported to be impaired
in uremic patients1,2 with a potential negative impact on
metabolic and nutritional state. The current data show that
impaired muscle mitochondrial enzyme activities are an early
alteration in moderate CKD, which could involve a low
transcriptional expression of mitochondrial biogenesis and
lipid metabolism regulators. Most importantly, these changes
are completely normalized by 14-day peripheral ghrelin
treatment. Restored oxidative capacity could improve lipid
oxidation,5,6 and the current data support this hypothesis by
showing a reduced tissue triglyceride content. Importantly,
ghrelin-induced changes in muscle energy and lipid meta-
bolism were independent of changes in food intake, thereby
showing the emerging independent in vivo role of ghrelin as a
positive modulator of muscle mitochondrial function in
wasting disease conditions as well.10
Muscle lipid accumulation is commonly associated with
tissue insulin resistance,5,6 and enhanced mitochondrial
oxidative capacity with lower triglyceride content was
accordingly associated with activation of insulin signaling
at the AKT level. Although it must be pointed out that
clinical studies particularly in growth-hormone-deficient
humans reported an acute negative impact of ghrelin on
whole-body insulin sensitivity,19,20 the current observation is
in agreement with reports on both acute and chronic ghrelin
treatment conditions,11,21 as well as with a bulk of studies
showing a positive association between ghrelin and insulin
action in humans,12,13,22,23 including nondiabetic patients
undergoing hemodialysis treatment.14 However, pair-feeding
studies further showed that ghrelin effects to stimulate
muscle insulin signaling and preserve lean body mass require
the ghrelin-induced stimulation of food intake. The associa-
tion of low food intake, wasting, and insulin resistance is
common in CKD,24,25 and current findings provide new
evidence for an independent positive effect of nutrition on
muscle AKT phosphorylation and lean mass accrual, at least
under ghrelin-treated conditions. Our results conversely
indicate that the previously reported effect of ghrelin to
stimulate muscle insulin action in healthy rodents11 does not
occur in anorectic CKD animals. These studies were not
aimed at elucidating the mechanisms linking enhanced food
intake and AKT phosphorylation. In the current model, the
independent effect of ghrelin on muscle mitochondria and
lipid content could have directly favored the increase of AKT
phosphorylation and lean mass preservation in ad libitum-
fed animals.1–6 A detrimental effect of negative energy balance
on muscle AKT phosphorylation through yet undefined
mechanisms has been directly suggested by studies in
fasting healthy humans, with opposite effects induced by
refeeding.26,27 Overall, the current combined results identify
novel interactions between ghrelin-induced independent
stimulation of appetite and muscle mitochondrial function,
leading to enhanced muscle AKT phosphorylation and
representing an effective tool to counteract wasting and loss
of lean body mass in CKD.
Inflammation has been shown to impair both muscle
mitochondrial function28 and insulin action.29 Systemic
inflammation is common in CKD24,30 and was activated in
the current model as indicated by proinflammatory changes
in circulating cytokines.16 Ghrelin treatment resulted in lower
plasma concentrations of proinflammatory cytokines,16
consistent with reported in vitro anti-inflammatory ghrelin
effects.31 It is therefore possible that lower inflammation also
contributed to beneficial ghrelin effects on muscle oxidative
capacity, and that it favored AKT phosphorylation in ad
libitum-fed animals. Lower inflammation could have also
directly contributed to preserve lean mass, as it has been
shown to directly impair skeletal muscle protein anabolism
by stimulating ubiquitin-dependent protein breakdown.32,33
These catabolic effects have been shown to involve IKB
Kinase beta/nuclear factor kappa B (IKKb/NF-kB) activa-
tion32 and stimulation of skeletal muscle suppressor of
cytokine signaling.33 Adipose tissue adipokines also con-
tribute to regulate systemic inflammation,34 as well as energy
metabolism and insulin action, with a major anti-inflamma-
tory and insulin-sensitizing role for adiponectin.34 Plasma
total adiponectin concentration was also measured in this
study to determine the potential effects of ghrelin on
adipokine secretion patterns. The expected CKD-induced
adiponectin elevation was, however, not altered by ghrelin
treatments, suggesting that altered patterns of adipose-
specific hormone production and/or secretion were unlikely
to mediate ghrelin-induced beneficial metabolic effects in this
model, in agreement with our previous results in healthy
rodents.11
Lower plasma glucose in ghrelin-treated animals supports
a direct effect of skeletal muscle changes on whole-body
glucose metabolism. However, it should be pointed out that
ghrelin was reported to increase plasma glucose concentra-
tion independently of food intake under different physiolo-
gical conditions,10,20 likely, at least in part, because of
stimulation of endogenous hepatic glucose production.10,35
Different experimental conditions due to disease- or model-
specific alterations could have contributed to differential
ghrelin effects on plasma glucose in these studies. Anti-
inflammatory changes in circulating cytokine patterns16
could have also favorably affected hepatic insulin action,
potentially resulting in lower gluconeogenesis29,36 and
contributing to a lower plasma glucose concentration.
Further studies are needed to directly test this hypothesis.
The current findings are finally in agreement with previous
data from an experimental cancer model15 in showing no
effect of ghrelin to preserve fat mass, which declined during
treatment in the presence of attenuated anorexia as well. This
observation suggests that, in wasting disease models, ghrelin
treatment favors the use of additional exogenous energy
intake to preserve lean body mass, at least in part through
direct stimulation of muscle energy metabolism and possibly
by lowering systemic inflammation.
In conclusion, ghrelin normalized a CKD-associated
reduction in skeletal muscle mitochondrial enzyme activities
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and expression of mitochondrial lipid metabolism regulators
independently of food intake, with a parallel reduction in
tissue triglyceride deposition. Ghrelin-induced stimulation of
muscle mitochondrial function and attenuated anorexia seem
to synergistically interact to enhance muscle AKT phosphor-
ylation and likely favor lean mass preservation. Novel
interactions between ghrelin effects on appetite and inter-
mediate metabolism improve CKD-associated metabolic and
nutritional alterations, thereby potentially reducing morbid-
ity and mortality in CKD.
MATERIALS AND METHODS
Animals and experimental design
Studies were approved by the Institutional Animal Care and Use
Committee of the Oregon Health and Science University and were
conducted according to the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. F344/NTacfBR male rats
(Taconic Farms, Germantown, Hudson, NY, USA) were housed two
per cage, fed rat chow (Diet 5001, Purina Mills, St Louis, MO, USA),
and acclimated for at least 3 days before use. This study was
designed to determine the effects of ghrelin and ghrelin analog
administration on body weight and composition in CKD, and part
of the study results have been published elsewhere.16 The 5/6
nephrectomy, sham operation, and placement of Alzet osmotic
mini-pumps (Model 2002; Durect, Cupertino, CA, USA) for 14-day
human ghrelin or vehicle subcutaneous infusion were previously
described.16 The day before pump implantation, the mean body
weight of each group was determined and the ghrelin concentration
required for the treatment group was determined on the basis of
ghrelin molecular weight and pump delivery rate in order to
administer 150 nmol ghrelin per kg per day. Before administration,
human ghrelin was dissolved in vehicle solution (2% inactivated rat
serum saline, 5% Tween-80), sonicated, and filtered through a 0.2-ml
syringe filter. Body composition was determined by dual-energy
X-ray absorptiometry (DEXA, Discovery A -QDR Series, Hologic,
Waltham, MA, USA) 2 days before the second stage of nephrectomy
or sham operation under anesthesia and on day 14 of compound
treatment, before killing with CO2. After killing the animals, blood
and gastrocnemius muscle samples were collected; muscles were
immediately frozen and kept at 80 1C until further analyses. For
the current set of measurements, 20 nephrectomized animals
receiving vehicle and 21 receiving ghrelin were studied, with 11
sham-operated controls. Of the ghrelin-treated animals, 11 were
allowed free access to food (Neph-Ghrelin), whereas 10 were pair-
fed to the food intake of vehicle-infused animals (Neph-GhrelinPF)
to further dissect the relative contributions to metabolic changes of
ghrelin treatment per se and ghrelin-induced attenuation of anorexia.
Cytochrome c oxidase and citrate synthase activity,
and RNA analysis
Mitochondrial cytochrome c oxidase and citrate synthase enzyme
activities were measured spectrophotometrically from muscle homo-
genates as referenced.10 Total RNA was isolated from 40mg of muscle
by the guanidinium method (Tri Reagent, MRC, Cincinnati, OH,
USA). Transcript levels of regulators of mitochondrial biogenesis and
lipid metabolism were measured by real-time PCR (7900 Sequence
Detection System, Applied Biosystems, Applied Biosystems Italia,
Monza, Italy) as referenced.10 Briefly, 1mg of total RNA was reverse-
transcribed (RNA Reverse Transcription KIT, Applied Biosystems) and
amplified using primers (300nM) and probes (50 nM) selected using
the Primer Express Software (Applied Biosystems).10 Primers for PGC-
1b amplification were as follows: forward: agcaagctctgatgctctgaagga;
reverse: accgaagtgaggtgcttatgcagt. The probe sequence for PGC-1b
detection was ttccagaagtcagcggccttgtgtcaa. 28S rRNA was used as
reference gene. Target and housekeeping genes were amplified
separately and their final quantitation was achieved using a relative
standard curve. Results for each gene were divided by the
corresponding 28S rRNA abundance and expressed as arbitrary units.
Tissue triglycerides, insulin signaling, and plasma
biochemical profile
Triglyceride content was measured from 35 to 40mg of muscle.10
Total (T) and phosphorylated (P: activated) AKT muscle
protein contents were determined using western blotting as
previously described.11 The P/T ratio was calculated as a marker of
tissue AKTactivation,11 and results were expressed as a percentage of
sham value. Plasma insulin concentrations were measured by
radioimmunoassay using a commercially available kit (Linco, St
Louis, MO, USA).10 Plasma total adiponectin was measured
using a commercially available ELISA kit (B-Bridge International,
Mountain View, CA, USA). Plasma creatinine, blood urea
nitrogen, glucose, and triglycerides were measured using standard
methods.
Statistical analysis
Results in the different experimental groups were compared using
one-way analysis of variance. Student’s t-test for unpaired data was
then used to compare results between two groups when significant
differences were detected by ANOVA. P-values of o0.05 were
considered to be statistically significant.
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